VivoSeq
Other

Blepharospasm

0

Pipeline Programs↗

2

Active Trials↗

3

Companies Involved↗

Blepharospasm is an early-stage landscape with 0 programs across 3 companies. The most active players are Merz Pharmaceuticals GmbH, Addex Pharma S.A., AbbVie.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

67/100

Attrition Rate

22/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

M

Merz Pharmaceuticals GmbH

0 programs

PreclinicalA

Addex Pharma S.A.

0 programs

PreclinicalAbbVie logo

AbbVie

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

9

clinical trials

Completed4 · 44%
Terminated2 · 22%
Not yet recruiting1 · 11%
Recruiting1 · 11%
Unknown status1 · 11%

Clinical Trials

Trial Activity

9 trials

Effects of DaxibotulinumtoxinA for Blepharospasm and Hemifacial Spasm
Recruiting·MMontefiore Medical Center·Phase 4·NCT06195241·40 enrolled
DaxibotulinumtoxinA for Blepharospasm
Not yet recruiting·UUniversity of Pennsylvania·Phase 2·NCT07489430·20 enrolled
Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm
Completed·AAddex Pharma S.A.·Phase 2·NCT05027997·15 enrolled
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm
Completed·MMerz Pharmaceuticals GmbH·Phase 3·NCT00406367·109 enrolled
Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm
Completed·AbbVie logoAbbVie·Phase 4·NCT00761592·65 enrolled
A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of Blepharospasm
Completed·National Institute of Neurological Disorders and Stroke (NINDS)·Phase 1/2·NCT00942851·24 enrolled
Blepharospasm Short Interval
Terminated·MMerz Pharmaceuticals GmbH·Phase 2·NCT00507637·8 enrolled
Acetyl Hexapeptide-8 for Blepharospasm
Terminated·National Institute of Neurological Disorders and Stroke (NINDS)·Phase 2·NCT01750346·8 enrolled
Wumeiwan Jiawei Fang Use in Patients With Blepharospasm
Unknown status·CChina Academy of Chinese Medical Sciences·Phase 2/3·NCT05618470·80 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)